-
Mashup Score: 5Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer - 9 month(s) ago
PURPOSE Current guidelines recommend molecular genotyping for patients newly diagnosed with metastatic nonsquamous (mNSq) non–small-cell lung cancer (NSCLC). The association between availability of molecular genotyping before first line (1L) therapy and overall survival (OS) is not known. METHODS We conducted a real-world cohort study using electronic health records in patients newly diagnosed with mNSq NSCLC. Cox proportional-hazards multivariable regression models were constructed to examine the association between OS and test result availability before 1L therapy, adjusting for covariates. Additional analyses were conducted to assess the consistency and strength of the relationship. Multivariable logistic regression models were used to examine the association between concurrent tissue and plasma testing (v tissue alone) and result availability. RESULTS Three hundred twenty-six patients were included, 80% (261/326) with results available before 1L (available testing group), and 20% (
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Plasma-Based Genotyping for Personalized Therapy in Metastatic Non–Small Cell Lung Cancer - 9 month(s) ago
This study assesses whether plasma-based next-generation sequencing was associated with improved mutation detection and enhanced delivery of personalized therapy in a real-world clinical setting of patients with non–small cell lung cancer.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
We evaluated 335 pts, majority of whom had undergone biomarker testing prior to start of 1L therapy, many by virtue of concurrent Tissue and Plasma NGS, which is our standard at Penn, based on earlier work https://t.co/k6fSiX8BXO https://t.co/2afDDgU17w
-
-
Mashup Score: 0Telehealth ReseArch Center of Excellence (TRACE) at the University of Pennsylvania - PC3I - 9 month(s) ago
The University of Pennsylvania Telehealth Research Center of Excellence is dedicated to advancing the nation’s telehealth research agenda.
Source: pc3i.upenn.eduCategories: Hem/Oncs, Latest HeadlinesTweet-
We are continuing this work with several efforts: ➡️Randomized Trial of early molecular testing #TESTING @NCI #Telehealth https://t.co/cGsI9nD3Jq ➡️ #iNUDGE - Implementation of EMR based "Nudges" https://t.co/eh2cACcj6g https://t.co/hXBogeqSIk
-
-
Mashup Score: 1Comprehensive molecular testing in lung cancer ‘absolutely crucial’ yet underutilized - 9 month(s) ago
Precision medicine has shown great potential to improve treatment outcomes and prolong survival of patients with lung cancer, as biomarker-driven therapies continue to extend their reach in this space.According to International Association for the Study of Lung Cancer, more than half of patients with lung cancer have tumors that harbor potentially actionable driver mutations. Therapies targeting
Source: www.healio.comCategories: Hem/Oncs, Latest HeadlinesTweet-
In summary, every patient with advanced #NSCLC should undergo #ComprehensiveMolecularGenotyping with broad panel #NGS to ensure delivery of appropriate therapy! https://t.co/7ozABwtYWc https://t.co/wZWfHDVqep
-
-
Mashup Score: 6Program Guide – ASCO Meeting Program Guide - 11 month(s) ago
AuthorsShinya SakataDepartment of Respiratory Medicine, Kumamoto University Hospital, Kumamoto, NA, JapanShinya Sakata, Hiroaki Akamatsu, Koichi Azuma, Takehiro Uemura, Yuko Tsuchiya-Kawano, Hiroshige Yoshioka, Mitsuo Osuga, Yasuhiro Koh, Satoshi Morita, Nobuyuki YamamotoOrganizationsDepartment of Respiratory Medicine, Kumamoto University Hospital, Kumamoto, NA, Japan, Internal Medicine III,…
Source: meetings.asco.orgCategories: Latest Headlines, Oncologists1Tweet-
#ASCO23 @ASCO Abs#9006 SCARLET: Ph II study of sotorasib + carbo/pem in #NSCLC w/ , WJOG14821L ➡️ N=30, 1L ➡️ PFS NR Need longer f/u. https://t.co/4AMAZI8z6S @KRASKickers @OncoAlert @HemOncToday
-
-
Mashup Score: 5Program Guide – ASCO Meeting Program Guide - 11 month(s) ago
AuthorsMengzhao WangDepartment of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaMengzhao Wang, Yun Fan, Meili Sun, Yongsheng Wang, Yanqiu Zhao, Bo Jin, Ying Hu, Zhigang Han, Xia Song, Anwen Liu, Kejing Tang, Ding Cuimin, Li Liang, Lin Wu, Junzhen Gao, Jianghong Wang, Ying Cheng,…
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
#ASCO23 @ASCO Abs#9002 Results of DZD9008 - sunvozertinib in pts w/ exon 20 #EGFR mutation @Exon20Group ➡️ Median 2L of prior tx ➡️ ORR ~61%, N=100 ➡️ ORR 48.5% in baseline brain mets ➡️ DoR 11 mo https://t.co/ZfJY1gbtoS @OncoAlert @HemOncToday
-
-
Mashup Score: 1Association of Immunotherapy Duration With Overall Survival in Advanced Non–Small Cell Lung Cancer - 11 month(s) ago
This cohort study of advanced non–small cell lung cancer patients assesses practice patterns surrounding immunotherapy discontinuation at 2 years and evaluates the association of duration of therapy with overall survival.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @TOGAANZ: Link to paper https://t.co/XVFmWZkHq5
-
-
Mashup Score: 0
As clinicians, we strive to integrate the strongest evidence to support optimal management, but every day we are forced to make clinical decisions without comparative data providing a clear path. For patients with advanced non–small cell lung cancer (NSCLC) who receive an immune checkpoint inhibitor…
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Just published in @JAMAOnc w/ an editorial by @JackWestMD Duration of ICI in #NSCLC https://t.co/8X6jYN3m8D @OncoAlert @LovaSunMD @MMarmarelis @Ron_cology #LCSM @ASCO #ASCO23 https://t.co/vpEsER7fLE
-
-
Mashup Score: 1ASCO Annual Meeting 2023: Improving Patients' Lives Through Collaboration, Research, and Innovation - 11 month(s) ago
The ASCO Annual Meeting is being held June 2 to 6, and here is some of the notable research that will be presented today. Topics include treatment for anemia related to myelodysplastic syndromes, pembrolizumab for advanced cervical cancer, surgery options for early pancreatic cancer, weight loss in breast cancer survivorship, the effect of Medicare expansion on racial disparities, and…
Source: Cancer.NetCategories: Hem/Oncs, Latest HeadlinesTweet-
Welcome aboard @PGrivasMDPhD! Thrilled to have you join the @CancerDotNet team! It has been a highlight of my volunteer service @ASCO. Patients/ Advocates/ Caregivers: Check out #ASCO23 blog focused on the latest research! https://t.co/LoYbeiT8SQ @montypal @JPatelMD https://t.co/sujlMDnoMQ
-
-
Mashup Score: 19Program Guide – ASCO Meeting Program Guide - 11 month(s) ago
ASCO-SEP 2022 Digital SubscriptionA comprehensive program for your self-assessment needs includes all-digital SEP® content (22 chapters + more chapter questions), an updated Question Bank, and additional educational resources. Subscribe today!
Source: meetings.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
#ASCO23 @ASCO Integrating #LiquidBx Into Patient Care and Clinical Trial Design Mon, Jun 5, 445CDT https://t.co/LHzgeyl4Y8 @lillian_siu @geoff_oxnard @ChristianRolfo @drgandara https://t.co/MuaoDlAYHI
-
We know that #ComprehensiveMolecularGenotyping is essential in patients with advanced #NSCLC - but do we know if availability of results impacts #Survival? In a real world cohort study, we asked this question @MMarmarelis - out now in @JCOPO_ASCO @ASCO 👉🏽https://t.co/C5ZLAhKdZl https://t.co/B1undVKBlr